New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
18:07 EDTCLDNCelladon 4M share Secondary priced at $9.50
Credit Suisse and Jefferies acted as joint book running managers for the offering.
News For CLDN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 22, 2015
11:08 EDTCLDNCelladon price target raised to $29 from $17 at Wedbush
Wedbush sees a 60% chance that Celladon's Mydicar will demonstrate a statistically significant benefit versus placebo in the primary endpoint of its Phase 2 CUPID2 trial involving patients with advanced systolic heart failure. The firm sees only a 30% likelihood that the primary endpoint won't be met, and a 10% chance that the outcome is so dramatic that the treatment will be approved by the FDA on an accelerated timetable. The firm says that, after other events that affected the company have passed, the stock's risk/reward ratio is almost entirely based on the possible outcome of the CUPID2 trial. It keeps an Outperform rating on the shares.
January 12, 2015
07:21 EDTCLDNEBD Group to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use